Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Jennerex has announced positive clinical data from Phase 2 trial of JX594, a proprietary, engineered oncolytic immunotherapy, in sorafenib-refractory hepatocellular carcinoma (liver cancer, HCC) patients.
Subscribe to our email newsletter
The evaluation of the safety of JX594 followed by sorafenib in patients with advanced HCC was the primary objective of the study while secondary endpoints included the effect of the sequential treatment of JX594 followed by sorafenib on disease control and tumour response.
The JX594 was shown to be safely delivered through systemic route, and sorafenib can be safely administered sequentially after JX594.
Jennerex R&D president, founder and chief medical officer David Kirn said JX594 demonstrated its ability to selectively target and destroy tumours following intravenous infusion in the Phase 2 trial.
"This finding confirms the ability of JX594 to target both primary and metastatic, or distant, tumours which we believe is important in this HCC patient population and most cancers," Kirn added.
The sequential treatment regimen was well tolerated demonstating JX594 side effects such as transient flu-like symptoms and transient leucopoenia. The sorafenib side effects observed were consistent with the expected toxicity profile of the product.
Both sorafenib-naïve and sorafenib-refractory patients demonstrated evidence of antitumor activity.